Delve into the world of diabetes treatment innovation with leading diabetology expert and grab latest insights on Imeglimin, a dual-action novel agent for Type 2 Diabetes Mellitus (T2DM). In this session, you'll gain insights into the Imeglimin's mechanism of action at a cellular and molecular level, clinical efficacy, and potential advantages of Imeglimin in managing T2DM. Join us for a comprehensive overview of this promising therapeutic option that may shape the future of diabetes care.

Imeglimin - The Dual Action Novel Agent for T2DM

Sr. Endocrinologist, Apollo Speciality Hospitals, Chennai, Specializes in type 1 & type 2 diabetes, endocrine disorders, thyroid disorders, and hormonal disorders.

Dr. Krishna Seshadri

-

-

-

-

Sessions Taken

781

4.7